Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
A Phase II Study of TAK-228 in patients with previously treated metastatic renal cell carcinoma
- ClinicalTrials.gov Identifier: NCT03097328
- Protocol Number: 16-527
- Principal Investigator: David McDermott
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required